0RP.F TIZIANA LIFE SCIENCES LTD

Healthcare Biotechnology Frankfurt Exchange
0.5450 EUR
Close of Nov 11, 2026
0.5450 1.58
Market cap
EUR 69.4M
P/E
-
P/B
2,465.72x
ROE
-35,444.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 0RP.F undervalued?

Graham number

The Graham number of TIZIANA LIFE SCIENCES LTD cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TIZIANA LIFE SCIENCES LTD fundamental analysis

No fundamental analysis for TIZIANA LIFE SCIENCES LTD yet.

TIZIANA LIFE SCIENCES LTD stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TIZIANA LIFE SCIENCES LTD

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a …

Full company profile